quinolones

Summary

Summary: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.

Top Publications

  1. ncbi Mechanisms of resistance to quinolones
    George A Jacoby
    Lahey Clinic, Burlington, Massachusetts 01805, USA
    Clin Infect Dis 41:S120-6. 2005
  2. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
  3. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
  4. ncbi Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules
    Paul Williams
    Centre for Biomolecular Sciences, University of Nottingham, United Kingdom
    Curr Opin Microbiol 12:182-91. 2009
  5. pmc Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa
    E C Pesci
    Department of Microbiology, East Carolina University School of Medicine, Greenville, NC 27858, USA
    Proc Natl Acad Sci U S A 96:11229-34. 1999
  6. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
  7. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
  8. pmc Plasmid-mediated quinolone resistance: a multifaceted threat
    Jacob Strahilevitz
    Department of Clinical Microbiology and Infectious Diseases, Hadassah Ein Kerem, Jerusalem 91120, Israel
    Clin Microbiol Rev 22:664-89. 2009
  9. ncbi The worldwide emergence of plasmid-mediated quinolone resistance
    Ari Robicsek
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Lancet Infect Dis 6:629-40. 2006
  10. pmc DNA gyrase, topoisomerase IV, and the 4-quinolones
    K Drlica
    Public Health Research Institute, New York, New York 10016, USA
    Microbiol Mol Biol Rev 61:377-92. 1997

Detail Information

Publications342 found, 100 shown here

  1. ncbi Mechanisms of resistance to quinolones
    George A Jacoby
    Lahey Clinic, Burlington, Massachusetts 01805, USA
    Clin Infect Dis 41:S120-6. 2005
    ..Resistance to quinolones can also be mediated by plasmids that produce the Qnr protein, which protects the quinolone targets from ..
  2. ncbi Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
    Donald A Mahler
    Section of Pulmonary and Critical Care Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
    Thorax 67:781-8. 2012
    ..The authors investigated the approach of dual bronchodilation using indacaterol, a once-daily long-acting β(2) agonist, and the long-acting muscarinic antagonist tiotropium, compared with tiotropium alone...
  3. ncbi Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium
    James F Donohue
    University of North Carolina, 4125 Bioinformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC, USA
    Am J Respir Crit Care Med 182:155-62. 2010
    ..Indacaterol is the first once-daily, long-acting inhaled beta(2)-agonist bronchodilator studied in patients with chronic obstructive pulmonary disease (COPD)...
  4. ncbi Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: a tale of regulatory networks and multifunctional signal molecules
    Paul Williams
    Centre for Biomolecular Sciences, University of Nottingham, United Kingdom
    Curr Opin Microbiol 12:182-91. 2009
    ....
  5. pmc Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa
    E C Pesci
    Department of Microbiology, East Carolina University School of Medicine, Greenville, NC 27858, USA
    Proc Natl Acad Sci U S A 96:11229-34. 1999
    ..aeruginosa cell-to-cell signaling is not restricted to acyl-homoserine lactones...
  6. ncbi Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD
    Ronald Dahl
    Department of Respiratory Diseases, Aarhus University Hospital, Aarhus, Denmark
    Thorax 65:473-9. 2010
    ..In previous studies, indacaterol provided 24 h bronchodilation on once-daily dosing with a fast onset of action. This study compared the efficacy and safety of indacaterol with the twice-daily LABA formoterol and placebo over 1 year...
  7. ncbi Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison
    O Kornmann
    Pulmonary Division, Internal Medicine, University Hospital, Mainz, Germany
    Eur Respir J 37:273-9. 2011
    ..Indacaterol should prove a useful additional treatment for patients with COPD...
  8. pmc Plasmid-mediated quinolone resistance: a multifaceted threat
    Jacob Strahilevitz
    Department of Clinical Microbiology and Infectious Diseases, Hadassah Ein Kerem, Jerusalem 91120, Israel
    Clin Microbiol Rev 22:664-89. 2009
    ..These proteins reduce susceptibility to quinolones by protecting the complex of DNA and DNA gyrase or topoisomerase IV enzymes from the inhibitory effect of ..
  9. ncbi The worldwide emergence of plasmid-mediated quinolone resistance
    Ari Robicsek
    Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Lancet Infect Dis 6:629-40. 2006
    ..develops in exquisitely susceptible organisms, or for the very strong association between resistance to quinolones and to other agents...
  10. pmc DNA gyrase, topoisomerase IV, and the 4-quinolones
    K Drlica
    Public Health Research Institute, New York, New York 10016, USA
    Microbiol Mol Biol Rev 61:377-92. 1997
    ..Moreover, topoisomerase IV is a target of the 4-quinolones, antibacterial agents that had previously been thought to target only gyrase...
  11. pmc Functions required for extracellular quinolone signaling by Pseudomonas aeruginosa
    Larry A Gallagher
    Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA
    J Bacteriol 184:6472-80. 2002
    ..Others of the pleiotropic phenazine-minus mutations appear to inactivate novel components of the quorum-sensing regulatory network, including one regulator (np20) previously shown to be required for virulence in neutropenic mice...
  12. ncbi Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD
    R Buhl
    Pulmonary Department, Mainz University Hospital, Langenbeckstrasse 1, Mainz, D 55131, Germany
    Eur Respir J 38:797-803. 2011
    ..Both bronchodilators demonstrated spirometric efficacy. The two treatments were well tolerated with similar adverse event profiles. Compared with tiotropium, indacaterol provided significantly greater improvements in clinical outcomes...
  13. pmc Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    BMC Pulm Med 12:29. 2012
    ....
  14. pmc Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
    Frank J Accurso
    University of Colorado Denver and Children s Hospital, Aurora, CO 80045, USA
    N Engl J Med 363:1991-2003. 2010
    ..VX-770, a CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface CFTR in vitro...
  15. ncbi Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review
    Gustavo J Rodrigo
    Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, 11300 Uruguay
    Chest 142:1104-10. 2012
    ..Bronchodilators are central to the symptomatic management of patients with COPD.Previous data have shown that inhaled indacaterol improved numerous clinical outcomes over placebo...
  16. ncbi Cellular characterization of a novel focal adhesion kinase inhibitor
    Jill K Slack-Davis
    Department of Microbiology and Cancer Center, Health Sciences System, University of Virginia, Charlottesville, Virginia 22908, USA
    J Biol Chem 282:14845-52. 2007
    ....
  17. ncbi Effect of indacaterol on exercise endurance and lung hyperinflation in COPD
    Denis E O'Donnell
    Queen s University and Kingston General Hospital, Kingston, Ontario K7L 2V7, Canada
    Respir Med 105:1030-6. 2011
    ..This study investigated the effect of indacaterol on exercise endurance, and on lung hyperinflation during exercise and at rest in patients with moderate-to-severe COPD...
  18. ncbi Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, ON, Canada
    Chest 140:68-75. 2011
    ..Indacaterol is an inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily dosing in patients with COPD...
  19. ncbi QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Heerlen, The Netherlands
    Thorax 65:1086-91. 2010
    ....
  20. ncbi Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients
    R M Mroz
    Department of Lung Diseases, Medical University of Bialystok, Zurawia 14, Bialystok, Poland
    Adv Exp Med Biol 756:23-8. 2013
    ..The patients' quality of life also changed favorably in the indacaterol treatment arm. We conclude that the add-on therapy with indacaterol exerts positive effects in COPD patients...
  21. ncbi Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies
    Edward M Kerwin
    Clinical Research Institute of Southern Oregon PC, Medford, Oregon 97504, USA
    Clin Ther 33:1974-84. 2011
    ....
  22. ncbi Type IIA topoisomerase inhibition by a new class of antibacterial agents
    Benjamin D Bax
    Molecular Discovery Research, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
    Nature 466:935-40. 2010
    ..This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class...
  23. ncbi Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases
    Ivan Laponogov
    Randall Division of Cell and Molecular Biophysics, King s College London, University of London, London, UK
    Nat Struct Mol Biol 16:667-9. 2009
    ..These structures reveal two drug molecules intercalated at the highly bent DNA gate and help explain antibacterial quinolone action and resistance...
  24. ncbi Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
    Alexandre Wohlkonig
    Platform Technology and Science, GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire, UK
    Nat Struct Mol Biol 17:1152-3. 2010
    ..This provides a molecular basis for the quinolone inhibition mechanism, resistance mutations and invariant quinolone antibacterial structural features...
  25. pmc qnrD, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin
    L M Cavaco
    Research Group for Antimicrobial Resistance and Molecular Epidemiology, National Food Institute, Technical University of Denmark, Copenhagen V
    Antimicrob Agents Chemother 53:603-8. 2009
    ..A phylogenetic analysis of all known qnr sequences was performed and showed that qnrD was more closely related to the qnrB variants but formed an independent cluster. To our knowledge, this is the first description of this qnrD gene...
  26. pmc New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis
    Minghua Wang
    Institute of Antibiotics, Huashan Hospital, Fudan University, 12 M Wulumuqi Rd, Shanghai 200040, People s Republic of China
    Antimicrob Agents Chemother 53:1892-7. 2009
    ..qnrC could not be detected by PCR, however, in 2,020 strains of Enterobacteriaceae. A new quinolone resistance gene, qnrC, was thus characterized from plasmid pHS10 carried by a clinical isolate of P. mirabilis...
  27. ncbi Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study
    Stephanie Korn
    Pulmonary Department, Mainz University Hospital, Mainz, Germany
    Respir Med 105:719-26. 2011
    ..Indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of COPD...
  28. pmc Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study
    Gregory Feldman
    S Carolina Pharmaceutical Research, Spartanburg, SC, USA
    BMC Pulm Med 10:11. 2010
    ..This 12-week, double-blind study compared the efficacy, safety, and tolerability of indacaterol to that of placebo in patients with moderate-to-severe COPD...
  29. ncbi Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3
    Wei Tien Tai
    Department of Medical Research, National Taiwan University Hospital, Chung Shan S Rd, Taipei 100, Taiwan
    Mol Cancer Ther 11:452-63. 2012
    ..In conclusion, dovitinib induces significant apoptosis in HCC cells and sorafenib-resistant cells via SHP-1-mediated inhibition of STAT3...
  30. pmc Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
    Didier Renard
    Novartis Pharma AG, Basel, Switzerland
    Respir Res 12:54. 2011
    ..We considered alternative methods of analysis...
  31. ncbi The Pseudomonas aeruginosa 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment
    Stephen P Diggle
    Institute of Infection, Immunity and Inflammation, Centre for Biomolecular Sciences, University Park, University of Nottingham, Nottingham NG7 2RD, United Kingdom
    Chem Biol 14:87-96. 2007
    ..Biophysical analysis revealed that 2-alkyl-3-hydroxy-4-quinolones form complexes with iron(III) at physiological pH...
  32. ncbi Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial
    Joo Cheol Shim
    Clinical Trial Center, Department of Psychiatry and Clinical Pharmacology, Busan Paik Hospital, Inje University, Busan 614 735, Republic of Korea
    Am J Psychiatry 164:1404-10. 2007
    ..The authors investigated the effect of adjunctive treatment with aripiprazole on hyperprolactinemia and psychopathology in patients with schizophrenia maintained with haloperidol...
  33. pmc Unexpected occurrence of plasmid-mediated quinolone resistance determinants in environmental Aeromonas spp
    Vincent Cattoir
    Institut Nationale de la Santé et de la Recherche Médicale Unité 914, Le Kremlin Bicetre, France
    Emerg Infect Dis 14:231-7. 2008
    ..The qnrS2 gene was located on IncU-type plasmids in both isolates, which resulted in increased MIC values of quinolones and fluoroquinolones, once they were transferred into Escherichia coli. The qnrS2 gene identified in A...
  34. pmc Safety of indacaterol in the treatment of patients with COPD
    James F Donohue
    University of North Carolina, Chapel Hill, NC 27599, USA
    Int J Chron Obstruct Pulmon Dis 6:477-92. 2011
    ..Pooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2)-agonist for chronic obstructive pulmonary disease (COPD)...
  35. ncbi Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates
    Vincent Cattoir
    Service de Bacteriologie Virologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Faculte de Medecine Paris Sud, Universite Paris XI, 78, rue du General Leclerc, 94275 K Bicêtre, France
    J Antimicrob Chemother 60:394-7. 2007
    ..To develop a rapid and reliable single-tube-based PCR technique for detecting simultaneously the plasmid-mediated quinolone resistance qnrA, qnrB and qnrS genes...
  36. pmc Regulation of Pseudomonas quinolone signal synthesis in Pseudomonas aeruginosa
    Dana S Wade
    Department of Microbiology and Immunology, East Carolina University School of Medicine, BT 132, 600 Moye Blvd, Greenville, NC 27834, USA
    J Bacteriol 187:4372-80. 2005
    ..These results suggest that a regulatory chain occurs where pqsR is under the control of LasR and RhlR and where PqsR in turn controls pqsABCDE, which is required for the production of PQS...
  37. ncbi Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection
    Joaquim Ruiz
    Department of Microbiology, Institut Clinic Infeccions i Immunologia, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    J Antimicrob Chemother 51:1109-17. 2003
    b>Quinolones are broad-spectrum antibacterial agents, commonly used in both clinical and veterinary medicine. Their extensive use has resulted in bacteria rapidly developing resistance to these agents...
  38. ncbi In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models
    Sang Hoon Lee
    Department of Pharmacology, Chiron Corp, Emeryville, California, USA
    Clin Cancer Res 11:3633-41. 2005
    ..To evaluate the therapeutic and biological effects of CHIR-258, an orally bioavailable, potent inhibitor of class III-V receptor tyrosine kinases, in colon cancer models...
  39. pmc Quinolones: from antibiotics to autoinducers
    Stephan Heeb
    School of Molecular Medical Sciences, Centre for Biomolecular Sciences, University Park, University of Nottingham, Nottingham, UK
    FEMS Microbiol Rev 35:247-74. 2011
    ..Pseudomonas aeruginosa and related bacteria produce a number of 2-alkyl-4(1H)-quinolones, some of which exhibit antimicrobial activity...
  40. pmc Quinolones: action and resistance updated
    Karl Drlica
    Public Health Research Institute, New Jersey Medical School, UMDNJ, 225 Warren Street, Newark, NJ 07103, USA
    Curr Top Med Chem 9:981-98. 2009
    The quinolones trap DNA gyrase and DNA topoisomerase IV on DNA as complexes in which the DNA is broken but constrained by protein...
  41. ncbi Electrospray/mass spectrometric identification and analysis of 4-hydroxy-2-alkylquinolines (HAQs) produced by Pseudomonas aeruginosa
    Francois Lepine
    INRS Institut Armand Frappier, Laval, Quebec, Canada
    J Am Soc Mass Spectrom 15:862-9. 2004
    ..aeruginosa, and provides insight into N-oxides biosynthesis and confirm the hypothesis that N-oxides are the precursors of compounds from Series 6 and 7...
  42. ncbi MvfR, a key Pseudomonas aeruginosa pathogenicity LTTR-class regulatory protein, has dual ligands
    Gaoping Xiao
    Department of Surgery, Harvard Medical School, Massachusetts General Hospital, USA
    Mol Microbiol 62:1689-99. 2006
    ..These results uncover a novel biological role for HHQ; and provide novel insights on MvfR activation that may aid in the development of therapies that prevent or treat P. aeruginosa infections in humans...
  43. ncbi Indacaterol once-daily is equally effective dosed in the evening or morning in COPD
    H Magnussen
    Pulmonary Research Institute, Hospital Grosshansdorf, Grosshansdorf, Germany
    Respir Med 104:1869-76. 2010
    ..05); and the % of days able to perform usual activities (by 6.7 and 7.8 points; p < 0.05). Indacaterol provided 24-h bronchodilation and improvement in symptoms regardless of whether taken regularly in the morning or evening...
  44. ncbi Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma
    Kevin B Kim
    Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Clin Cancer Res 17:7451-61. 2011
    ..This phase I/II dose-escalation study was conducted to evaluate the safety, pharmacodynamics, and preliminary efficacy of dovitinib in the treatment of advanced melanoma...
  45. pmc Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment
    Jingjing Zhao
    College of Veterinary Medicine, National Reference Laboratory of Veterinary Drug Residues SCAU, South China Agricultural University, Guangzhou 510642, China
    Antimicrob Agents Chemother 54:4219-24. 2010
    ..Transconjugants carrying oqxAB showed 4- to 16-fold increases in the MICs of quinolones, 16- to 64-fold increases in the MICs of quinoxalines, 8- to 32-fold increases in the MICs of chloramphenicol ..
  46. ncbi Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study
    Masaharu Kinoshita
    Nagata Hospital, Fukuoka, Japan
    Respirology 17:379-89. 2012
    ..This study was primarily designed to obtain the regulatory approval of indacaterol in Japan...
  47. ncbi Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia
    Meliha Meric
    Department of Clinical Bacteriology and Infectious Diseases, Medical Faculty, Kocaeli University, Kocaeli, Turkey
    APMIS 116:66-73. 2008
    ..These results suggest that antimicrobial treatment should be started early, and quinolones such as moxifloxacin and ciprofloxacin seem to be new alternatives in the treatment of oropharyngeal tularemia.
  48. pmc Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis
    Paul W Jones
    Division of Clinical Science, St George s, University of London, London, UK
    Respir Res 12:161. 2011
    ..We examined whether changes in trough forced expiratory volume in 1 second (FEV(1)) are correlated with changes in patient-reported outcomes...
  49. ncbi Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium
    Andrea Rossi
    Unità Operativa Complessa di Pneumologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
    Respir Med 106:84-90. 2012
    ..Evidence has been provided that high-dose indacaterol (300 μg) can reduce lung hyperinflation in moderate-to-severe chronic obstructive pulmonary disease (COPD)...
  50. ncbi Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Value Health 15:524-33. 2012
    ..Indacaterol trial evidence was synthesized to provide coherent estimates of indacaterol 150 μg and indacaterol 300 μg relative to formoterol, salmeterol, and tiotropium...
  51. ncbi Insight into the mechanism of laquinimod action
    W Bruck
    Department of Neuropathology, University Medical Center, Georg August University, Gottingen, Germany
    J Neurol Sci 306:173-9. 2011
    ..In conclusion, treatment with laquinimod is effective in reducing inflammation, demyelination and axonal damage...
  52. pmc Mechanism of plasmid-mediated quinolone resistance
    John H Tran
    Infectious Disease Department, Lahey Clinic, Burlington, MA 01805, USA
    Proc Natl Acad Sci U S A 99:5638-42. 2002
    b>Quinolones are potent antibacterial agents that specifically target bacterial DNA gyrase and topoisomerase IV. Widespread use of these agents has contributed to the rise of bacterial quinolone resistance...
  53. pmc Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas aeruginosa
    T Kohler
    Department of Genetics and Microbiology, Centre Medical Universitaire, CH 1211 Geneva 4, Switzerland
    J Bacteriol 183:5213-22. 2001
    ..Transcription of an rhlAB-lacZ fusion could be partially restored by the addition of synthetic C4-HSL and Pseudomonas quinolone signal (PQS). It is proposed that the MexEF-OprN efflux pump affects intracellular PQS levels...
  54. pmc Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents
    Christoph U Correll
    Zucker Hillside Hospital, Psychiatry Research, North Shore Long Island Jewish Health System, 75 59 263rd St, Glen Oaks, NY 11004, USA
    JAMA 302:1765-73. 2009
    ..Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication...
  55. pmc Origin of plasmid-mediated quinolone resistance determinant QnrA
    Laurent Poirel
    Service de Bacteriologie Virologie, Hopital de Bicetre, 78, rue du General Leclerc, 94275 Le Kremlin Bicetre, France
    Antimicrob Agents Chemother 49:3523-5. 2005
    Plasmid-mediated resistance to quinolones is increasingly reported in studies of Enterobacteriaceae. Using a PCR-based strategy, a series of gram-negative species were screened for qnrA-like genes...
  56. pmc High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofur-resistant Enterobacteriaceae isolates from companion and food-producing animals
    Junying Ma
    College of Veterinary Medicine, National Reference Laboratory of Veterinary Drug Residues, South China Agricultural University, Guangzhou
    Antimicrob Agents Chemother 53:519-24. 2009
    ..PMQR determinants are highly prevalent in ceftiofur-resistant Enterobacteriaceae strains isolated from animals in China. This is the first report of the occurrence of PMQR determinants among isolates from companion animals...
  57. ncbi Dueling quorum sensing systems in Pseudomonas aeruginosa control the production of the Pseudomonas quinolone signal (PQS)
    Stephen McGrath
    Department of Microbiology and Immunology, The Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA
    FEMS Microbiol Lett 230:27-34. 2004
    ..These data are an important early step toward understanding the regulation of PQS synthesis and the role of PQS in P. aeruginosa intercellular signaling...
  58. pmc Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
    Claus Vogelmeier
    Novartis Pharmaceuticals Inc, One Health Plaza, East Hanover, NJ 07936 1080, USA
    Respir Res 11:135. 2010
    ..This randomized, double-blind study compared the bronchodilator efficacy of indacaterol with that of placebo and tiotropium in patients with moderate-to-severe COPD...
  59. ncbi Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae
    Patrice Nordmann
    Service de Bacteriologie Virologie, Hopital de Bicetre, Assistance Publique Hopitaux de Paris, Faculte de Medecine Paris Sud, Universite Paris Sud, 78 rue du General Leclerc, 94275, K Bicêtre, France
    J Antimicrob Chemother 56:463-9. 2005
    ..Qnr proteins protect DNA from quinolone binding and compromise the efficacy of quinolones such as nalidixic acid...
  60. ncbi Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD
    Kai Michael Beeh
    insaf Respiratory Research Institute, D 65187 Wiesbaden, Germany
    COPD 8:340-5. 2011
    ..In conclusion, indacaterol 300 μg administered once-daily showed a clinically relevant increase in IC after 14 days of treatment, reflecting a reduction in dynamic hyperinflation...
  61. ncbi Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients
    Boudewijn Van de Maele
    AZ Sint Jan Brugge Oostende AV, Campus H Serruys, Oostende, Belgium
    COPD 7:418-27. 2010
    ..Once-daily QVA149 was well tolerated in COPD patients with a cardiovascular safety profile and overall adverse event rates similar to placebo...
  62. pmc Transcriptomic analysis reveals a global alkyl-quinolone-independent regulatory role for PqsE in facilitating the environmental adaptation of Pseudomonas aeruginosa to plant and animal hosts
    Giordano Rampioni
    School of Molecular Medical Sciences, Centre for Biomolecular Sciences, University Park, University of Nottingham, Nottingham NG7 2RD, UK
    Environ Microbiol 12:1659-73. 2010
    ..Taken together these data reveal that PqsE is a key regulator within the QS circuitry facilitating the environmental adaptation of P. aeruginosa...
  63. ncbi Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD
    Heinrich Worth
    Medical Department I, Klinikum Fürth, Jakob Henle Str 1, D 90766 Fürth, Germany
    Respir Med 105:571-9. 2011
    ..As COPD patients commonly suffer cardio- and cerebrovascular (CCV) co-morbidities, our purpose was to establish the CCV safety profile of indacaterol, a novel, inhaled, long-acting β(2)-agonist for COPD...
  64. pmc Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Int J Chron Obstruct Pulmon Dis 7:415-20. 2012
    ....
  65. ncbi Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis
    J Wang
    Department of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
    J Clin Pharm Ther 37:204-11. 2012
    ..However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations...
  66. pmc Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
    Eugene R Bleecker
    Center for Genomics and Personalized Medicine Research and Translational Medicine Institute, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Int J Chron Obstruct Pulmon Dis 6:431-8. 2011
    ..As indacaterol is the first once-daily β(2)-agonist to be developed, it is relevant to evaluate its bronchodilator efficacy, safety, and tolerability...
  67. pmc Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica
    Deborah J Eaves
    Antimicrobial Agents Research Group, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom
    Antimicrob Agents Chemother 48:4012-5. 2004
    ..Although it is counterintuitive, isolates with a mutation in both gyrA and parC were more susceptible to ciprofloxacin than were isolates with a mutation in gyrA alone...
  68. ncbi Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis
    Wolfgang Bruck
    Department of Neuropathology, University Medical Center Gottingen, Robert Koch Street 40, 37075 Gottingen, Germany
    Expert Rev Clin Pharmacol 5:245-56. 2012
    ..In conclusion, preclinical studies show that laquinimod's unique mechanisms of action, including its immunomodulatory and CNS-protective effects, translate into clinical benefits in relapsing-remitting multiple sclerosis patients...
  69. pmc Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in Toxoplasma gondii
    San San Lin
    Institute of Medical Microbiology, University of Gottingen, Kreuzbergring 57, D 37075 Gottingen, Germany
    Eukaryot Cell 8:877-87. 2009
    ....
  70. pmc Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the new transmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wil
    L M Cavaco
    Research Group for Antimicrobial Resistance and Molecular Epidemiology, Department for Microbiology and Risk Assessment, National Food Institute, Technical University of Denmark, Bulowsvej 27, Copenhagen V DK 1790, Denmark
    J Clin Microbiol 47:2751-8. 2009
    ..The aim of this study was to compare the ability of the screening of the different quinolones by disk diffusion assays and MIC determinations to detect fluoroquinolone resistance...
  71. ncbi A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder
    Ronald N Marcus
    Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA
    J Am Acad Child Adolesc Psychiatry 48:1110-9. 2009
    ..To evaluate the short-term efficacy and safety of aripiprazole in the treatment of irritability in children and adolescents with autistic disorder...
  72. ncbi Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study
    G Comi
    Department of Neurology, University Vita Salute and Scientific Institute San Raffaele, Milan, Italy
    Mult Scler 16:1360-6. 2010
    ..Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing-remitting MS (RRMS) patients...
  73. pmc Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD
    Kenneth R Chapman
    Asthma and Airway Centre, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada
    Int J Chron Obstruct Pulmon Dis 6:353-63. 2011
    ..These are important factors for optimum dose delivery and successful COPD management...
  74. pmc Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis
    Shannon Cope
    Mapi Values, Boston, MA, USA
    Int J Chron Obstruct Pulmon Dis 6:329-44. 2011
    ....
  75. ncbi In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones
    A Aranda
    Research Unit for Allergic Diseases, Malaga, Spain
    Allergy 66:247-54. 2011
    Hypersensitivity IgE-mediated reactions to quinolones are not easy to diagnose, with skin testing inducing false positive results...
  76. ncbi Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia
    G Grunder
    Klinik fur Psychiatrie und Psychotherapie, Universitatsklinikum Aachen, RWTH Aachen, Germany
    Pharmacopsychiatry 39:S21-5. 2006
    ..Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein...
  77. ncbi Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
    T Sudo
    Thrombosis and Vascular Research Laboratory, Otsuka Pharmaceutical Co, Ltd, Tokushima, Japan
    Biochem Pharmacol 59:347-56. 2000
    ..998). These data demonstrated that OPC-33540 is a highly selective and potent PDE3 inhibitor and a useful probe for identification of the intracellular functions of PDE3...
  78. ncbi Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa
    Elisabeth Kugelberg
    Swedish Institute for Infectious Disease Control, Department of Bacteriology, S 171 82 Solna, Sweden
    J Antimicrob Chemother 55:22-30. 2005
    ..We have analysed the effect of quinolone resistance caused by DNA gyrase/topoisomerase IV mutations on bacterial fitness...
  79. ncbi CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
    Suzanne Trudel
    Department of Medical Oncology, University Health Network, Princess Margaret Hospital and McLaughlin Centre of Molecular Medicine, University of Toronto, 620 University Ave, Rm 8 204, Toronto, ON, Canada M5G 2C1
    Blood 105:2941-8. 2005
    ..Finally, therapeutic efficacy of CHIR-258 was demonstrated in a xenograft mouse model of FGFR3 MM. These studies support the clinical evaluation of CHIR-258 in MM...
  80. ncbi HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens
    Daniel Da Silva
    Laboratoire de Virologie, Bordeaux University Hospital, and EA2968, Universite Victor Segalen, Bordeaux, France
    J Antimicrob Chemother 65:1262-9. 2010
    ..Our aim was to study the in vivo viral genetic pathways for resistance to raltegravir, in antiretroviral-experienced patients with virological failure (VF) on raltegravir-containing regimens...
  81. pmc Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase
    Jérémie Piton
    Unité de Dynamique Structurale des Macromolécules, Departement de Biologie Structurale et Chimie, Institut Pasteur, Paris, France
    PLoS ONE 5:e12245. 2010
    ..This interaction provides useful starting points for designing peptide based inhibitors that target DNA gyrase to prevent its binding to DNA...
  82. ncbi Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
    Christiane Wegner
    Department of Neuropathology, University Medical Center, Georg August University, Gottingen, Germany
    J Neuroimmunol 227:133-43. 2010
    ..Laquinimod might thus protect myelin and axons by decreasing pro-inflammatory cytokines and impairing the migratory capacity of lymphocytes...
  83. pmc Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli
    H Yoshida
    Research Laboratories, Dainippon Pharmaceutical Co, Ltd, Osaka, Japan
    Antimicrob Agents Chemother 35:1647-50. 1991
    ..Type 1 mutants were resistant to all the quinolones tested, while type 2 mutants were resistant to acidic quinolones and were hypersusceptible to amphoteric ..
  84. ncbi Probing the two-gate mechanism of DNA gyrase using cysteine cross-linking
    N L Williams
    Department of Biochemistry, University of Leicester, U K
    Biochemistry 38:13502-11. 1999
    ..This indicates that passage of DNA through the bottom dimer interface is not essential for this reaction. The mechanistic implications of these results are discussed...
  85. pmc Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors
    Olivia Goethals
    Tibotec BVBA, Mechelen, Belgium
    J Virol 82:10366-74. 2008
    ..These data broaden the understanding of antiviral resistance against integrase inhibitors and may give insight facilitating the discovery of second-generation compounds...
  86. ncbi Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design
    Peter J Barnes
    Imperial College, London, UK
    Pulm Pharmacol Ther 23:165-71. 2010
    ..This approach was used in a clinical study of indacaterol, a novel once-daily (od) inhaled long-acting beta(2)-adrenoreceptor agonist bronchodilator for the treatment of COPD (chronic obstructive pulmonary disease)...
  87. pmc qnr Gene nomenclature
    George Jacoby
    Lahey Clinic, Burlington, Massachusetts MA 01805, USA
    Antimicrob Agents Chemother 52:2297-9. 2008
  88. ncbi The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication
    Séverine Aendekerk
    Laboratory of Microbial Interactions, Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for Biotechnology, Vrije Universiteit Brussel, Building E, room 6 6, Pleinlaan 2, B 1050 Brussels, Belgium
    Microbiology 151:1113-25. 2005
    ..Collectively, these results demonstrate an essential function for the MexGHI-OpmD pump in facilitating cell-to-cell communication, antibiotic susceptibility and promoting virulence and growth in P. aeruginosa...
  89. pmc Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone
    Beatrix Balint
    Csongrád Megyei OnkormányzatMellkasi Betegségek Szakkórháza, Deszk, Hungary
    Int J Chron Obstruct Pulmon Dis 5:311-8. 2010
    ..indacaterol is a novel, inhaled once-daily ultra-long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease (COPD)...
  90. pmc In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues
    Wei Wang
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Clin Cancer Res 15:3511-8. 2009
    ....
  91. ncbi CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice
    Xiaohua Xin
    Translational Sciences, Chiron Corporation, Emeryville, California, USA
    Clin Cancer Res 12:4908-15. 2006
    ..This study assesses the antimyeloma activity of CHIR-258, a small-molecule inhibitor of multiple receptor tyrosine kinases that is currently in phase I trials, in a newly developed FGFR3-driven preclinical MM animal model...
  92. ncbi Mechanisms of quinolone action and microbial response
    Peter M Hawkey
    Public Health Laboratory, Heartlands Hospital, Bordesley Green East, Birmingham B5 9SS, UK
    J Antimicrob Chemother 51:29-35. 2003
    ..However, it is conceivable that in the future, horizontal gene transfer may become a more important means of conferring resistance to fluoroquinolones...
  93. pmc A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  94. ncbi Quinolones: review of psychiatric and neurological adverse reactions
    Ana M Tome
    Medical Department, Grupo Tecnimede, Sintra, Portugal
    Drug Saf 34:465-88. 2011
    b>Quinolones are a class of antibacterial agents for the treatment of several infectious diseases (e.g. urinary and respiratory tract infections)...
  95. pmc Aripiprazole in autism spectrum disorders and fragile X syndrome
    Craig A Erickson
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Neurotherapeutics 7:258-63. 2010
    ..However, research to date in this disorder has not focused on this target symptom cluster. An initial pilot study has begun to assess the impact of aripiprazole on irritability in youth with fragile X syndrome...
  96. ncbi Efficacy of indacaterol in the treatment of patients with COPD
    Paul W Jones
    Division of Clinical Sciences, St George s University of London, London, UK
    Prim Care Respir J 20:380-8. 2011
    ..The safety profile was similar to placebo. Once-daily indacaterol is an effective and beneficial maintenance bronchodilator treatment for patients with moderate-to-severe COPD...
  97. ncbi Aripiprazole protects cortical neurons from glutamate toxicity
    Vuk Koprivica
    CNS Drug Discovery and Development, Otsuka Maryland Medicinal Laboratories, Inc, Rockville, MD 20850, USA
    Eur J Pharmacol 651:73-6. 2011
    ..Further experiments are required to determine the biochemical nature of aripiprazole-induced neuroprotection and whether any such activity might have clinical relevance...
  98. ncbi The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition
    J G Heddle
    Department of Biochemistry, University of Leicester, Leicester, LE1 7RH, UK
    J Mol Biol 307:1223-34. 2001
    ..microcin B17 stabilises a gyrase-dependent DNA cleavage complex in a manner reminiscent of quinolones, Ca(2+), or the bacterial toxin CcdB...
  99. ncbi An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders
    Hanik K Yoo
    Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
    J Clin Psychiatry 68:1088-93. 2007
    ....
  100. ncbi Aripiprazole in patients with Tourette syndrome
    Emanuel Bubl
    Department of Psychiatry, Albert Ludwigs University, Freiburg, Germany
    World J Biol Psychiatry 7:123-5. 2006
    ..Furthermore, we discuss possible pharmacological mechanisms for the observed effects...
  101. pmc Differential immune modulatory activity of Pseudomonas aeruginosa quorum-sensing signal molecules
    Doreen S W Hooi
    School of Pharmacy, University of Nottingham, University Park, NG7 2RD, UK
    Infect Immun 72:6463-70. 2004
    ..aeruginosa, which are detectable endobronchially and may be active at the host/pathogen interface during infection with P. aeruginosa, should the bronchial airway lymphoid tissues prove to be accessible to QSSM...

Research Grants62

  1. Pilot-Scale Heterocyclic and Carbocyclic Libraries for High Throughout Screening
    RICHARD LAROCK; Fiscal Year: 2009
    ..diverse libraries of indoles, benzofurans, benzopyrans, coumarins, isocoumarins, phthalides, pyrones, 2-quinolones, pyridines, isoquinolin-1-ones, isoindolin-1-ones, isoquinolines, carbolines, isoindolo[2,1-a]indoles, ..
  2. Plasmid-Mediated Quinolone Resistance
    George A Jacoby; Fiscal Year: 2013
    Project Summary Quinolones have been very useful antimicrobial agents because they are highly potent, active against a wide range of bacteria, and relatively non-toxic...
  3. Processing and consequences of DNA-protein crosslinks in E. coli
    Kenneth N Kreuzer; Fiscal Year: 2012
    ..The first aim seeks to elucidate the mechanism of DNA breakage and cytotoxicity after treatment with quinolones, with an emphasis on the role of several genes including dnaQ, recQ, xseAB, and ruvAB...
  4. Iron and O2 in the Regulation of P. aeruginosa Virulence
    Michael L Vasil; Fiscal Year: 2012
    ..aeruginosa under iron replete conditions and inthe expression of quorum sensing compounds (quinolones - PQS), that are known to have a prominent impact on its virulence...
  5. An Integrated Diagnostic System for Rapid Antimicrobial Susceptibility Testing
    VINCENT JEN JR GAU; Fiscal Year: 2013
    ..With increasing use, however, SXT resistance increased substantially and quinolones such as ciprofloxacin (CIP) became the antibiotic of choice...
  6. Novel fluoroquinolones for killing dormant Mycobacterium tuberculosis
    Xilin Zhao; Fiscal Year: 2013
    ..tuberculosis and would thereby reduce treatment time radically. As part of their mechanism of action, quinolones trap DNA gyrase as drug-enzyme-DNA complexes in which the DNA is broken but held together by protein...
  7. Small Molecule Inhibitors of P. aeruginosa Quinolone (Pqs) Quorum Sensing
    Derek S Tan; Fiscal Year: 2013
    ..b>Quinolones are small molecules that are biosynthesized by the bacteria and used in cell-cell signaling...
  8. Cranberry: Interactions with Anti-infectious Agents
    Gail Anderson; Fiscal Year: 2005
    ..The bacterial pathogens in UTI are typically responsive to trimethoprim-sulfamethoxazole, quinolones, and the beta-lactams (penicillins, cephalosporins)...
  9. Small molecule inhibitors of bacterial iron acquisition systems
    Harry L Mobley; Fiscal Year: 2013
    ..Infections are routinely treated with antibiotics including trimethoprim- sulfamethoxazole or quinolones. While vaccine development is in the pipeline, there are no vaccines currently licensed for use in the U.S...
  10. Drugs targeting erythrocytic and exoerythrocytic stages of malaria
    Roman Manetsch; Fiscal Year: 2013
    ..Endochin and 4(1H)-quinolones are known to possess causal prophylactic activity (kill growing EE stage parasites) and potent erythrocytic ..
  11. Enhancement of antimicrobics by electrical current
    Robin Patel; Fiscal Year: 2007
    ..In vitro experiments have shown that electric current can enhance the activity of aminoglycosides, quinolones or oxytetracycline against bacteria in biofilms; this has been termed the 'bioelectric effect...
  12. Detecting Carbapenem and Quinolone Resistance in Klebsiella pneumoniae using PCR/
    Robert A Bonomo; Fiscal Year: 2010
    ..Gram-negative bacteria, nosocomial infections by Klebsiella pneumoniae that are resistant to carbapenems and quinolones are rapidly becoming a global problem...
  13. Novel antibacterials targeting the 50S ribosomal subunit
    Joyce Sutcliffe; Fiscal Year: 2005
    ..Looking ahead, this agent would cover strains that have resistance to macrolides, quinolones, vancomycin, ¿-lactams, Synercid(r), and Linezolid...
  14. PRECLINICAL DEVELOPMENT OF NEW ANTITUBERCULOSIS REGIMEN
    Leonid Heifets; Fiscal Year: 2000
    ..pyrazinamide, streptomycin,ethambutol, developed under this program or already available (for example, some quinolones and aminosidine)...
  15. Immunoprotective monoclonals to B. anthracis spores
    ALISON O BRIEN; Fiscal Year: 2003
    ..Indeed, the aggressive use of quinolones and other antibiotics coupled with the early recognition of disease resulted in the survival of 6 of the 11 ..
  16. Target for Mefloquine in Mycobacteria
    Luiz Bermudez; Fiscal Year: 2002
    ..Furthermore, mefloquine is active against M. avium strain resistant to macrolides, quinolones, isoniazid, ethambutol and rifampin, suggesting a novel mechanism of action...
  17. Novel Reactions of Arynes and their Application to the Synthesis of Anti-Cancer A
    KEITH MEAD; Fiscal Year: 2009
    ..that enimines prove to be superior agents for trapping arynes, the synthesis of 2-aryl-substituted quinolines, 4-quinolones, and quinolinequinones from quinolinium salts will take priority...
  18. Quinolone Action During Mycobacterial Growth Arrest
    Karl Drlica; Fiscal Year: 2006
    ..Exploitation of this pathway through changes in quinolone structure could, in principle, make the quinolones much more effective anti-bacterial agents. Since tuberculosis often includes a latent stage in which M...
  19. FOURTH CONFERENCE ON DNA TOPOISOMERASES IN THERAPY
    Milan Potmesil; Fiscal Year: 1992
    ..agents and their target DNA topoisomerase I or II, but also a closely related enzyme DNA gyrase targeted by quinolones and related drugs...
  20. Role of Quinolone Efflux Pumps in S. pneumoniae Resistance
    Michael Miller; Fiscal Year: 2004
    ..pneumoniae that is overexpressed in response to hydrophilic quinolones. We believe that this overexpression leads to an unnecessarily high rate of resistance...
  21. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  22. PROSPECTIVE STUDY OF TARDIVE DYSKINESIA DEVELOPMENT
    John Kane; Fiscal Year: 2001
    ..This strategy will provide a rapid and cost-effective answer to a critical question. ..
  23. Plasmid-Mediated Quinolone Resistance
    George Jacoby; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Quinolones are widely used antimicrobial agents because of their broad antibacterial spectrum, low toxicity, and reliable action against otherwise resistant pathogens...
  24. Farnesyltransferase Inhibitor Therapy for Myelodysplasia
    Razelle Kurzrock; Fiscal Year: 2002
    ....
  25. MECHANISMS OF TOPOISOMERASE POISONS
    Hiroshi Hiasa; Fiscal Year: 2002
    ..III) Recent studies have demonstrated that quinolones do not stimulate S. aureus DNA gyrase (Gyrase)-mediated DNA cleavages. We will characterize S...
  26. Exploratory Trial of Curcumin in Pancreatic Cancer
    Razelle Kurzrock; Fiscal Year: 2005
    ..These studies should provide the foundation for the development of curcumin as an anticancer agent and may lead to a novel approach to the management of pancreatic cancer. ..
  27. QUINOLONE RESISTANCE MECHANISMS IN STAPHYLOCOCCUS AUREUS
    David Hooper; Fiscal Year: 2007
    ..Long-term objectives of the project are to use quinolones and resistant mutants as a model system to study the control and function of topoisomerases and efflux pumps ..
  28. LONGITUDINAL FOLLOW UP OF ADHD GIRLS AND THEIR SIBLINGS
    Joseph Biederman; Fiscal Year: 2002
    ....
  29. Consortium Therapeutic Studies of Primary Central Nervous System Malignancies
    Timothy Cloughesy; Fiscal Year: 2008
    ..Finally, significant infrastructure expertise exists at UCLA to aide the consortium with needs that are important for the acceleration of brain cancer translational research. ..
  30. Course of psychopathology in female youth: Analysis with extant longitudinal data
    Joseph Biederman; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  31. Controlled Study of SAMe vs.Escitalopram in Major Depressive Disorder
    Maurizio Fava; Fiscal Year: 2008
    ..Secondary aims are to assess the acute effects of SAMe or escitalopram vs. placebo on remission rates, quality of life, and psychosocial functioning. ..
  32. REVAMP Follow-Up
    Madhukar Trivedi; Fiscal Year: 2008
    ....
  33. Zinc transport and homeostasis in cortical neurons
    Robert Colvin; Fiscal Year: 2002
    ..What is the identity of Zn2+ containing compartments in the cell body and processes of cortical neurons?..
  34. TREATMENT OF PANIC DISORDER--LONG TERM STRATEGIES
    Scott Woods; Fiscal Year: 2003
    ..Thus, we are proposing to add these aims. ..
  35. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....
  36. PREVENTION OF CIGARETTE SMOKING IN ADHD YOUTH
    Joseph Biederman; Fiscal Year: 2001
    ..Since there are estimated to be 3.5 million children with ADHD and 20% have been shown to be smokers, targeting this group could potentially impact 700,000 children and adolescents. ..
  37. Matching 5-HT Genotypes to Serotonergic Medications for Alcoholism
    GEORGE ANTHONY KENNA; Fiscal Year: 2010
    ....
  38. Apoptosis in myelofibrosis with myeloid metaplasia
    Ruben Mesa; Fiscal Year: 2006
    ..abstract_text> ..
  39. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  40. GLUCOCORTICOID REGULATION OF MEMORY IN AGING HUMANS
    John Newcomer; Fiscal Year: 2003
    ..g., GC receptor antagonists, calcium channel blockers) for preventing this adverse effect on memory. ..
  41. TREATMENT OF NEGATIVE SYMPTOMS & COGNITIVE IMPAIRMENTS
    Stephen Marder; Fiscal Year: 2003
    ..The study will provide new information on the efficacy of d- cycloserine and glycine for both persistent primary and secondary negative symptoms and its effect on cognitive functioning. ..
  42. Adult Outcome of Attention Deficit Hyperactivity Disorder
    Joseph Biederman; Fiscal Year: 2007
    ..For these reasons, we expect the proposed work to clarify the course and outcome of ADHD. ..
  43. MANAGEMENT FOR RISK OF RELAPSE IN SCHIZOPHRENIA
    Stephen Marder; Fiscal Year: 2004
    ..The investigator will evaluate outcome during the next two years with measures of clinical psychopathology, medication side effects, functional outcomes, and quality of life. ..
  44. TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC
    Scott Woods; Fiscal Year: 2004
    ..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
  45. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  46. Treatment with Exercise Augmentation for Depression
    Madhukar Trivedi; Fiscal Year: 2006
    ....
  47. Aripiprazole for Clozapine Associated Medical Morbidity
    David Henderson; Fiscal Year: 2007
    ..Clinical adjunctive therapy may establish aripiprazole as a new therapeutic approach in schizophrenia and clozapine-associated medical disorders. ..
  48. Collaborative Pediatric Bipolar Disorder Conference
    Joseph Biederman; Fiscal Year: 2007
    ..While the proposed conference does not intend to solve all outstanding problems associated with pediatric bipolar disorder, it will provide a forum to begin formulating a solution. ..
  49. Antipsychotic Medication
    John Newcomer; Fiscal Year: 2005
    ..Relevant data is critically needed to target basic research, identify long-term cardiovascular consequences, and plan therapeutic interventions. ..
  50. Enhancing the Prospective Prediction of Psychosis
    Scott Woods; Fiscal Year: 2007
    ..Each site has provefi its ability to recruit prodromal patients in a previous collaboration. ..
  51. DNA GYRASE AND QUINOLONE RESISTANCE IN TUBERCULOSIS
    Karl Drlica; Fiscal Year: 2007
    The goals of this program are to understand how the quinolones act in mycobacteri a and to discover ways to protect the compounds from the development of resistance...
  52. Computerized Decision Support System for Depression
    Madhukar Trivedi; Fiscal Year: 2007
    ..Comparisons will be made between CDSS-D, PPA-D, and UC-D. [unreadable] [unreadable]..
  53. Alternative endpoints for plague challenge models
    Richard Frothingham; Fiscal Year: 2005
    ..We will use the data generated to refine our hypotheses and to pursue further funding to complete Aim 3. ..
  54. Duke University Center for Translational Research
    Richard Frothingham; Fiscal Year: 2006
    ....
  55. TRAINING IN FUNCTIONAL IMAGING AND ALCOHOL WITHDRAWAL
    DONALD MYRICK; Fiscal Year: 2004
    ....
  56. Lapatinib in childhood CNS malignancies
    Maryam Fouladi; Fiscal Year: 2006
    ..These data will be used in the rational design of future phase I combination or frontline studies to improve the outcome in children with these poor prognosis tumors. [unreadable] [unreadable]..
  57. DOPAMINE AND GABA IMAGING IN SCHIZOPHRENIA
    Lawrence Kegeles; Fiscal Year: 2004
    ..abstract_text> ..
  58. Omega-3 Fatty Acids for Treatment of Major Depression
    David Mischoulon; Fiscal Year: 2010
    ..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
  59. Institute for Research Minority Training on Mental Health
    Jacobo Mintzer; Fiscal Year: 2007
    ..We expect this effort to be the incubator for a new generation of minority researchers dedicated to the study mental health and aging. ..
  60. TOPOISOMERASE I INHIBITORS IN LEUKEMIA AND SOLID TUMORS
    Scott H Kaufmann; Fiscal Year: 2010
    ..Collectively, these studies are designed to provide new insight into the mechanism of action of topo I poisons, and identify strategies for enhancing their efficacy. ..